Xyrem Related Published Studies
Well-designed clinical trials related to Xyrem (Sodium Oxybate)
Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study. [2011.05]
A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome. [2011.01]
The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. [2010.12.15]
Enhancing slow wave sleep with sodium oxybate reduces the behavioral and physiological impact of sleep loss. [2010.09]
A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing. [2010.01]
Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: A randomized, double-blind, placebo-controlled, multicenter clinical trial. [2009.01]
A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. [2006.09.01]
Sodium oxybate improves excessive daytime sleepiness in narcolepsy. [2006.07.01]
Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. [2005.09]
Well-designed clinical trials possibly related to Xyrem (Sodium Oxybate)
Immunomodulating properties of gamma-hydroxybutyrate (GHB), flunitrazepam and ethanol in 'club drugs' users. [2010.07]
Exacerbation of cataplexy following gradual withdrawal of antidepressants: manifestation of probable protracted rebound cataplexy. [2009.04]
Piracetam improves children's memory after general anaesthesia. [2009.01]
Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. [2007.12]
Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. [2007.02]
Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam. [2007]
Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. [2006.11]
Gamma-hydroxybutyrate and ethanol effects and interactions in humans. [2006.10]
Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionst. [2006.09]
Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. [2006.08]
GHB urine concentrations after single-dose administration in humans. [2006.07]
Other research related to Xyrem (Sodium Oxybate)
Sodium oxybate for the treatment of fibromyalgia. [2011.08]
Long-term efficacy of sodium oxybate in 4 patients with chronic cluster headache. [2011.07.05]
Sodium oxybate-induced sleep driving and sleep-related eating disorder. [2011.06.15]
Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. [2011.06]
Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. [2011.06]
Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study. [2011.04]
Sodium oxybate increases prolactin secretion in narcolepsy patients and healthy controls. [2011.03]
Long-term follow-up of patients with narcolepsy-cataplexy treated with sodium oxybate (Xyrem). [2011.01]
Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience. [2011]
Effects of Sodium Oxybate on Sleep Physiology and Sleep/Wake-related Symptoms in Patients with Fibromyalgia Syndrome: A Double-blind, Randomized, Placebo-controlled Study. [2010.10]
Sodium oxybate in the treatment of binge eating disorder: An open-label, prospective study. [2010.03.05]
Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. [2010.02]
Treatment of the narcoleptiform sleep disorder in chronic fatigue syndrome and fibromyalgia with sodium oxybate. [2010.01]
The nightly use of sodium oxybate is associated with a reduction in nocturnal
sleep disruption: a double-blind, placebo-controlled study in patients with
narcolepsy. [2010]
Enhancing slow wave sleep with sodium oxybate reduces the behavioral and
physiological impact of sleep loss. [2010]
A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute
effects on sleep-disordered breathing. [2010]
The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. [2009.09]
Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. [2009.09]
Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. [2009.08.15]
Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. [2009.07]
Weight loss in narcolepsy patients treated with sodium oxybate. [2009.06]
Successful treatment of REM sleep behavior disorder with sodium oxybate. [2009.05]
Three deaths associated with use of Xyrem. [2009.04]
A patient with intractable posthypoxic myoclonus (Lance-Adams syndrome) treated with sodium oxybate. [2009.03]
A multi-drug intoxication fatality involving Xyrem (GHB). [2009.03]
[Integrated treatment of the symptoms of narcolepsy-cataplexy syndrome with sodium oxybate] [2009.01.01]
Precipitating pharmakologies and capital entrapments: narcolepsy and the strange cases of Provigil and Xyrem. [2009.01]
Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. [2008.10]
Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy. [2008.03]
Treatment of drop attacks in Coffin-Lowry syndrome with the use of sodium oxybate. [2007.11]
Sodium butyrate prevents lethality of severe sepsis in rats. [2007.06]
Restless legs syndrome in narcolepsy: a side effect of sodium oxybate? [2007.03]
Sodium oxybate: a review of its use in the management of narcolepsy. [2007]
Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. [2006.08.01]
Sodium oxybate for narcolepsy. [2006.08]
Effect of sodium hydroxybutyrate on the expression of hippocampal N-methyl-D-aspartate receptor 2B subunit mRNA in neonatal rats with hypoxic-ischemic insult. [2006.06]
Sodium oxybate for cataplexy. [2006.03]
A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. [2005.12.27]
A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. [2005.10]
Marked amelioration of alcohol-responsive posthypoxic myoclonus by gamma-hydroxybutyric acid (Xyrem). [2005.06]
Sodium oxybate for the treatment of narcolepsy. [2005.02]
Other possibly related research studies
Lack of effects of GHB precursors GBL and 1,4-BD following i.c.v. administration in rats. [2006.11]
Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons. [2006.11]
Induction of apoptosis by the 16-kDa amino-terminal fragment of the insulin-like growth factor binding protein 3 in human colonic carcinoma cells. [2006.11]
Flexible intensive insulin therapy in adults with type 1 diabetes and high risk for severe hypoglycemia and diabetic ketoacidosis. [2006.10]
EFNS guidelines on management of narcolepsy. [2006.10]
[Chemical submission: a literature review] [2006.03]
Movement disorders and alcohol misuse. [2006.06]
Molecular genetics and treatment of narcolepsy. [2006]
A comprehensive study on the variations in urinary concentrations of endogenous gamma-hydroxybutyrate (GHB). [2006.03]
Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. [2006.02]
Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management. [2006]
Paroxysmal sympathetic surge associated with gamma hydroxybutyrate. [2006.02]
Discriminative stimulus effects of gamma-hydroxybutyrate: role of training dose. [2006.04]
Molecular genetic advances in sleep research and their relevance to sleep medicine. [2005.03.01]
Unusually high concentrations in a fatal GHB case. [2005.09]
Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. [2006.02.28]
Distribution of GHB in tissues and fluids following a fatal overdose. [2005.07]
Recent trends in the use of "club drugs": an Australian review. [2005]
A brief overview of the clinical pharmacology of "club drugs". [2005]
Successful treatment of narcolepsy and cataplexy: a review. [2005.05]
Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report. [2005]
Agitation is common in gamma-hydroxybutyrate toxicity. [2005.05]
Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. [2005.05]
Gamma hydroxy butyrate abuse and dependency. [2005.03]
[Gamma-hydroxybutyrate (GHB) misuse or abuse and interpretation of toxicological findings] [2005.01]
Physostigmine does not effect arousal but produces toxicity in an animal model of severe gamma-hydroxybutyrate intoxication. [2005.03]
Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons. [2005.05]
Best evidence topic report: endotracheal intubation in gamma-hydroxybutyric acid intoxication and overdose. [2005.01]
[Gamma-hydroxybutyrate--a neurotransmitter, medicine, and drug] [2005.07]
Narcolepsy and the hypocretin system--where motion meets emotion. [2006.10]
Emerging therapies in narcolepsy-cataplexy. [2005.06.01]
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. [2005]
Benzylpiperizine-based party pills' impact on the Auckland City Hospital Emergency Department Overdose Database (2002-2004) compared with ecstasy (MDMA or methylene dioxymethamphetamine), gamma hydroxybutyrate (GHB), amphetamines, cocaine, and alcohol. [2007.02.16]
Low-carb diets, fasting and euphoria: Is there a link between ketosis and gamma-hydroxybutyrate (GHB)? [2007]
Survival of massive gamma-hydroxybutyrate/1,4-butanediol overdose. [2005.06]
[Narcolepsy: a new perspective on diagnosis and treatment] [2007.04.14]
Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. [2007]
Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. [2007.06]
[Fibromyalgia syndrome : New developments in pharmacotherapy.] [2007.10.10]
Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study. [2007.06]
|
